Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival

Ted S. Gansler, William Jackson Hardman, Dirk A. Hunt, Steven Schaffel, Randolph A. Hennigar

Research output: Contribution to journalArticle

213 Citations (Scopus)

Abstract

Certain cancers exhibit derangement of de novo fatty acid biosynthesis, manifested as overexpression and hyperactivity of the lipogenic enzyme fatty acid synthase (FAS). Correlation of elevated FAS with high tumor grade and advanced stage in primary breast, prostate, and colorectal cancers has drawn attention to the enzyme as a possible marker of poor prognosis. To find a similar utility of FAS in ovarian neoplasms, we compared FAS expression in 68 ovarian tumors with their histological features and clinical outcome. Immunohistochemical localization of FAS was observed in 48 (71%) cases in which staining was either focal (defined as positive staining in 1% to 20% of cells) or multifocal/diffuse (positive staining in >20% of cells). Most (83%) of the 48 cases were represented by endometrioid, serous, or mucinous carcinomas and malignant mixed mullerian tumors (MMMTs). In contrast, ovarian adenomas and tumors of low malignant potential (LMPs) contained little or no FAS. Association between FAS expression and histological diagnosis was statistically significant. The extent of FAS immunostaining was also predictive of prognosis. Among all patients with ovarian malignancies (including LMPs), median survival was 64.8 months, when their tumors exhibited no or focal immunostaining for FAS, as opposed to 31.2 months, when staining was multifocal/diffuse (P = .005). Similar median survival values were obtained when cases were limited to endometrioid, serous, and mucinous carcinomas. Short-term survival at 1 and 2 years was significantly higher in patients whose tumors showed no or focal expression of FAS compared with multifocal/diffuse expression. Thus, elevated FAS may serve as an independent marker for predicting poor clinical outcome in patients with ovarian cancer.

Original languageEnglish (US)
Pages (from-to)686-692
Number of pages7
JournalHuman Pathology
Volume28
Issue number6
DOIs
StatePublished - Jan 1 1997

Fingerprint

Fatty Acid Synthases
Ovarian Neoplasms
Survival
Neoplasms
Staining and Labeling
Endometrioid Carcinoma
Mucinous Adenocarcinoma
Malignant Mixed Tumor
Enzymes
Adenoma
Colorectal Neoplasms
Prostatic Neoplasms
Fatty Acids

Keywords

  • Fatty acid synthase
  • Lipid metabolism
  • Ovarian cancer
  • Prognostic markers

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. / Gansler, Ted S.; Hardman, William Jackson; Hunt, Dirk A.; Schaffel, Steven; Hennigar, Randolph A.

In: Human Pathology, Vol. 28, No. 6, 01.01.1997, p. 686-692.

Research output: Contribution to journalArticle

Gansler, Ted S. ; Hardman, William Jackson ; Hunt, Dirk A. ; Schaffel, Steven ; Hennigar, Randolph A. / Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. In: Human Pathology. 1997 ; Vol. 28, No. 6. pp. 686-692.
@article{1a6615d38a714056b0f35d1b573e8751,
title = "Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival",
abstract = "Certain cancers exhibit derangement of de novo fatty acid biosynthesis, manifested as overexpression and hyperactivity of the lipogenic enzyme fatty acid synthase (FAS). Correlation of elevated FAS with high tumor grade and advanced stage in primary breast, prostate, and colorectal cancers has drawn attention to the enzyme as a possible marker of poor prognosis. To find a similar utility of FAS in ovarian neoplasms, we compared FAS expression in 68 ovarian tumors with their histological features and clinical outcome. Immunohistochemical localization of FAS was observed in 48 (71{\%}) cases in which staining was either focal (defined as positive staining in 1{\%} to 20{\%} of cells) or multifocal/diffuse (positive staining in >20{\%} of cells). Most (83{\%}) of the 48 cases were represented by endometrioid, serous, or mucinous carcinomas and malignant mixed mullerian tumors (MMMTs). In contrast, ovarian adenomas and tumors of low malignant potential (LMPs) contained little or no FAS. Association between FAS expression and histological diagnosis was statistically significant. The extent of FAS immunostaining was also predictive of prognosis. Among all patients with ovarian malignancies (including LMPs), median survival was 64.8 months, when their tumors exhibited no or focal immunostaining for FAS, as opposed to 31.2 months, when staining was multifocal/diffuse (P = .005). Similar median survival values were obtained when cases were limited to endometrioid, serous, and mucinous carcinomas. Short-term survival at 1 and 2 years was significantly higher in patients whose tumors showed no or focal expression of FAS compared with multifocal/diffuse expression. Thus, elevated FAS may serve as an independent marker for predicting poor clinical outcome in patients with ovarian cancer.",
keywords = "Fatty acid synthase, Lipid metabolism, Ovarian cancer, Prognostic markers",
author = "Gansler, {Ted S.} and Hardman, {William Jackson} and Hunt, {Dirk A.} and Steven Schaffel and Hennigar, {Randolph A.}",
year = "1997",
month = "1",
day = "1",
doi = "10.1016/S0046-8177(97)90177-5",
language = "English (US)",
volume = "28",
pages = "686--692",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival

AU - Gansler, Ted S.

AU - Hardman, William Jackson

AU - Hunt, Dirk A.

AU - Schaffel, Steven

AU - Hennigar, Randolph A.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Certain cancers exhibit derangement of de novo fatty acid biosynthesis, manifested as overexpression and hyperactivity of the lipogenic enzyme fatty acid synthase (FAS). Correlation of elevated FAS with high tumor grade and advanced stage in primary breast, prostate, and colorectal cancers has drawn attention to the enzyme as a possible marker of poor prognosis. To find a similar utility of FAS in ovarian neoplasms, we compared FAS expression in 68 ovarian tumors with their histological features and clinical outcome. Immunohistochemical localization of FAS was observed in 48 (71%) cases in which staining was either focal (defined as positive staining in 1% to 20% of cells) or multifocal/diffuse (positive staining in >20% of cells). Most (83%) of the 48 cases were represented by endometrioid, serous, or mucinous carcinomas and malignant mixed mullerian tumors (MMMTs). In contrast, ovarian adenomas and tumors of low malignant potential (LMPs) contained little or no FAS. Association between FAS expression and histological diagnosis was statistically significant. The extent of FAS immunostaining was also predictive of prognosis. Among all patients with ovarian malignancies (including LMPs), median survival was 64.8 months, when their tumors exhibited no or focal immunostaining for FAS, as opposed to 31.2 months, when staining was multifocal/diffuse (P = .005). Similar median survival values were obtained when cases were limited to endometrioid, serous, and mucinous carcinomas. Short-term survival at 1 and 2 years was significantly higher in patients whose tumors showed no or focal expression of FAS compared with multifocal/diffuse expression. Thus, elevated FAS may serve as an independent marker for predicting poor clinical outcome in patients with ovarian cancer.

AB - Certain cancers exhibit derangement of de novo fatty acid biosynthesis, manifested as overexpression and hyperactivity of the lipogenic enzyme fatty acid synthase (FAS). Correlation of elevated FAS with high tumor grade and advanced stage in primary breast, prostate, and colorectal cancers has drawn attention to the enzyme as a possible marker of poor prognosis. To find a similar utility of FAS in ovarian neoplasms, we compared FAS expression in 68 ovarian tumors with their histological features and clinical outcome. Immunohistochemical localization of FAS was observed in 48 (71%) cases in which staining was either focal (defined as positive staining in 1% to 20% of cells) or multifocal/diffuse (positive staining in >20% of cells). Most (83%) of the 48 cases were represented by endometrioid, serous, or mucinous carcinomas and malignant mixed mullerian tumors (MMMTs). In contrast, ovarian adenomas and tumors of low malignant potential (LMPs) contained little or no FAS. Association between FAS expression and histological diagnosis was statistically significant. The extent of FAS immunostaining was also predictive of prognosis. Among all patients with ovarian malignancies (including LMPs), median survival was 64.8 months, when their tumors exhibited no or focal immunostaining for FAS, as opposed to 31.2 months, when staining was multifocal/diffuse (P = .005). Similar median survival values were obtained when cases were limited to endometrioid, serous, and mucinous carcinomas. Short-term survival at 1 and 2 years was significantly higher in patients whose tumors showed no or focal expression of FAS compared with multifocal/diffuse expression. Thus, elevated FAS may serve as an independent marker for predicting poor clinical outcome in patients with ovarian cancer.

KW - Fatty acid synthase

KW - Lipid metabolism

KW - Ovarian cancer

KW - Prognostic markers

UR - http://www.scopus.com/inward/record.url?scp=0031007392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031007392&partnerID=8YFLogxK

U2 - 10.1016/S0046-8177(97)90177-5

DO - 10.1016/S0046-8177(97)90177-5

M3 - Article

VL - 28

SP - 686

EP - 692

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 6

ER -